DaVita's Q3 earnings miss expectations, leading to a decline in share price, as the company faces cost and volume headwinds despite pockets of growth.
Dodgers' high-priced lineup struggles to produce offense, putting World Series title defense in jeopardy against the Blue Jays.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
DaVita's Q3 earnings miss expectations, leading to a decline in share price, as the company faces cost and volume headwinds despite pockets of growth.
Dodgers' high-priced lineup struggles to produce offense, putting World Series title defense in jeopardy against the Blue Jays.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.